Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax Vaccination at Least 5 Years Earlier

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax Vaccination at Least 5 Years Earlier

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs GSK 1437173A (Primary)
  • Indications Herpes zoster
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Acronyms Zoster-048
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Oct 2017 Primary endpoint (Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations-non-inferiority) has been met, according to results presented at the IDWeek 2017.
    • 08 Oct 2017 Results presented at the IDWeek 2017.
    • 26 Sep 2017 Results published in the Journal of Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top